Clinical outcome according to risk.

Influence of the dominant standard prognostic factors (β-2-microglobulin, C-reactive protein, duration of standard therapy prior to high-dose therapy) on event-free survival (A); overall survival (B); and CR duration (C). Four distinct risk groups can be distinguished on the basis of the number of unfavorable features present (for details, see text). Ratios denote the fraction of patients experiencing an event among those presenting with chromosome 13 deletion. Events and at risk values are for curves with 0 unfavorable characteristics.